Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook ...

The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

Heart valve disease is a fairly common problem that happens when at least one of your four heart valves isn’t working ...

With this expansion came a better understanding of associated complications. Spinal cord ischemia, perhaps the most dreaded complication of aortic surgery short of death, led to an understanding of ...

COLLEGEVILLE, PA — Thubrikar Aortic Valve, Inc. has announced promising outcomes from recent procedures involving its Optimum ...

Sumitomo Mitsui DS Asset Management Company Ltd trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by ...

Edwards Lifesciences (NYSE:EW – Get Free Report) will be releasing its earnings results after the market closes on Thursday, October 24th. Analysts expect Edwards Lifesciences to post earnings of ...

Innovations such as the RESILLIA technology enhance the performance of the company’s TAVR (Transcatheter Aortic Valve ... quarter driven by the SAPIEN 3 Ultra RESILIA valve.

EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third ...